Oragenics Inc. Common Stock
Key Metrics
Market Snapshot
About
Oragenics Inc. Common Stock (OGEN) is a development-stage company headquartered in Lakewood Ranch, Florida. It conducts research and development on nasal delivery pharmaceutical therapies aimed at neurological conditions and infectious diseases in the United States. As a development-stage business, its work centers on advancing experimental treatments rather than on selling marketed products. The company was incorporated in 1996 and was formerly known as Oragen, Inc.
The company's lead program is ONP-002, a fully synthetic, non-naturally occurring neurosteroid. This compound is lipophilic, which allows it to cross the blood-brain barrier. ONP-002 is being developed for mild traumatic brain injury, where it is designed to reduce swelling, oxidative stress, and inflammation while helping restore proper blood flow through gene amplification. This candidate reflects the company's focus on delivering therapies through the nasal route to reach the brain.
Because Oragenics Inc. is at the development stage, its progress depends on continued research and the advancement of its candidates through testing. Its emphasis on nasal delivery sets the approach it takes to reaching targets in the nervous system, and its stated interest in both neurological conditions and infectious diseases outlines the disease areas it aims to address. The development of ONP-002 for mild traumatic brain injury is the central focus described for the company, and its results will turn on how that program and any related work move forward. As a research driven organization, OGEN ties its outlook to the outcomes of its pipeline rather than to current product sales, working to build treatments around its nasal delivery platform.